Volume | 701,876 |
|
|||||
News | - | ||||||
Day High | 9.295 | Low High |
|||||
Day Low | 8.86 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Arcutis Biotherapeutics Inc | ARQT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
9.02 | 8.86 | 9.295 | 8.94 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
8,857 | 701,876 | $ 9.04 | $ 6,346,062 | - | 1.76 - 15.21 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:57:58 | 200 | $ 8.985 | USD |
Arcutis Biotherapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
865.51M | 96.81M | - | 59.61M | -262.14M | -2.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Arcutis Biotherapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARQT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 10.015 | 10.38 | 8.435 | 9.52 | 2,580,539 | -1.03 | -10.28% |
1 Month | 9.39 | 13.17 | 8.435 | 10.53 | 2,998,679 | -0.405 | -4.31% |
3 Months | 5.92 | 13.17 | 5.38 | 9.41 | 4,345,279 | 3.07 | 51.77% |
6 Months | 2.52 | 13.17 | 1.76 | 5.73 | 4,770,839 | 6.47 | 256.55% |
1 Year | 13.97 | 15.21 | 1.76 | 6.17 | 3,065,626 | -4.99 | -35.68% |
3 Years | 30.58 | 36.45 | 1.76 | 9.15 | 1,333,442 | -21.60 | -70.62% |
5 Years | 23.05 | 40.88 | 1.76 | 10.20 | 995,744 | -14.07 | -61.02% |
Arcutis Biotherapeutics Description
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate, roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |